Loading
Ten years after vaccination, Indian girls who had received a single dose of HPV vaccine were as well protected against the cancer-causing HPV types as those who had two or three doses, which let the world switch to one-dose programmes.
Multicentre prospective cohort study arising from an IARC trial at nine Indian centres whose recruitment was suspended in 2010, leaving cohorts of girls aged 10 to 18 who had received one (4,949), two (4,980) or three (4,348) doses of quadrivalent HPV vaccine. At a median follow-up of 9.0 years (IQR 8.2-9.6), vaccine efficacy against persistent HPV 16/18 infection was 95.4% (95% CI 85.0-99.9) after one dose, 93.1% (77.3-99.8) after two and 93.3% (77.5-99.7) after three, compared with unvaccinated married women of similar age.
One dose protects. WHO endorsed one- or two-dose schedules in 2022, halving the cost and the logistics of vaccinating girls, which is decisive for India (about 127,500 cervical cancers a year) and for the global elimination target. It also removed the main barrier to India's national programme with its home-made vaccine.
Shares KEN SHE (single-dose HPV vaccine), CERVAVAC (quadrivalent HPV vaccine, India), IARC India HPV vaccine dose study (one, two or three doses), Nonavalent HPV vaccine.
Shares CERVAVAC (quadrivalent HPV vaccine, India), Nonavalent HPV vaccine, HPV & HBV vaccination, Prevention we already have is not deployed.
Shares Rengaswamy Sankaranarayanan, IARC India HPV vaccine dose study (one, two or three doses), International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination.
Shares Nonavalent HPV vaccine, HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer.
Shares KEN SHE (single-dose HPV vaccine), Nonavalent HPV vaccine, HPV & HBV vaccination, Prevention we already have is not deployed.
Shares Rengaswamy Sankaranarayanan, International Agency for Research on Cancer (IARC / WHO), Prevention we already have is not deployed, Cervical cancer.
Shares International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer.
Shares International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination, Prevention we already have is not deployed, Cervical cancer.